Peculiarities of community-acquired pneumonia treatment in patients with COVID-19

Authors

  • Carolina Catcov IP Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, R. Moldova
  • Svetlana Chislaru Spitalul Clinic Municipal ,,Sf. Arhanghel Mihail”, Chişinău, R. Moldova
  • Ina Pogonea IP Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, R. Moldova
  • Nicolae Bacinschi IP Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, R. Moldova

DOI:

https://doi.org/10.52692/1857-0011.2021.1-69.22

Keywords:

Community-acquired pneumonia, COVID-19, antibacterial therapy

Abstract

The clinical picture (fever, cough, sputum, auscultatory changes), peripheral blood parameters (leukocytosis, ESR) and radiological data are currently the criteria for suspecting bacterial pneumonia in patients with SARS CoV-2 infection and for indication of antibacterial treatment. The initiation of antibiotic therapy is empirical by taking into account the pathogens most likely involved in community-acquired pneumonia (Str pneumoniae, St. aureus, Kl. pneumoniae, Haemofillus influenzae, Mecoplasma pneumoniae, Chlamydia, Ps. aeruginosa). Beta-lactams (cephalosporins, carbapenems), protected beta-lactams, macrolides and fluoroquinolones are the most commonly administered groups, and the combinations of cephalosporins + macrolides and cephalosporins + fluoroquinolones constitute the most used groups of antibacterial treatment in order to include bacterial flora, gram-positive or gram-negative, and atypical

Author Biographies

Ina Pogonea, IP Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, R. Moldova

dr. în şt. med., conf. univ

Nicolae Bacinschi, IP Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, R. Moldova

dr. hab. în şt. med., prof. univ

Published

2021-05-11

Issue

Section

Research Article